Publications by authors named "Francesco Loconsole"

Claim this Profile
S
Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study.
Riccardo Balestri, Giulia Odorici, Michela Magnano, Paolo Gisondi, Francesco Bellinato, Francesco Loconsole

J Eur Acad Dermatol Venereol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Francesco Loconsole

J Dermatolog Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis).
Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, Alessandra Narcisi, Luciano Ibba, Francesco Loconsole

Clin Exp Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).
Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, Antonio Costanzo, Matteo Bianco, Francesco Loconsole

Dermatol Ther (Heidelb)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift Programs.
Giulio Gualdi, Laura Bigi, Clara De Simone, Paolo Amerio, Francesco Loconsole

Dermatol Pract Concept· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study.
Luigi Gargiulo, Silvia M Ferrucci, Luciano Ibba, Ruggero Cascio Ingurgio, Angela Alfano, Francesco Loconsole

J Eur Acad Dermatol Venereol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis).
Mario Valenti, Luciano Ibba, Sara Di Giulio, Paolo Dapavo, Piergiorgio Malagoli, Francesco Loconsole

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, Matteo Megna, Annunziata Raimondo, Francesco Loconsole

Psoriasis (Auckl)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study.
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, Matteo Megna, Annunziata Raimondo, Francesco Loconsole

Clin Exp Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years.
Luca Mastorino, Paolo Dapavo, Martina Burlando, Paolo Gisondi, Carlo Alberto Maronese, Francesco Loconsole

Psoriasis (Auckl)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).
Helena Gioacchini, Agnese Rossi, Maria Esposito, Emanuele Vagnozzi, Maria Concetta Fargnoli, Francesco Loconsole

Dermatol Ther (Heidelb)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).
Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Francesco Loconsole

Dermatol Ther (Heidelb)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).
Maria Esposito, Paolo Gisondi, Chiara Assorgi, Francesco Bellinato, Pina Brianti, Francesco Loconsole

Clin Drug Investig· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD.
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, Luisa Angileri, Francesco Loconsole

Dermatitis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study.
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, Matteo Megna, Annunziata Raimondo, Francesco Loconsole

Dermatol Ther (Heidelb)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of treatment with biological drugs in psoriasis patients with a history of malignancies: a single-center observational study.
Edoardo Mortato, Giorgia Sbarra, Riccardo Viola, Alexandre R Meduri, Felice Primavera, Francesco Loconsole

Ital J Dermatol Venerol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis).
Matteo Megna, Diego Orsini, Chiara Assorgi, Anna Balato, Riccardo Balestri, Francesco Loconsole

Clin Exp Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity?
Gaetano Licata, Eugenia Veronica Di Brizzi, Franco Castelli, Giorgia Giuffrida, Elena Stroppiana, Francesco Loconsole

J Clin Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Francesco Loconsole

J Dermatolog Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of tildrakizumab 200 mg: an Italian multicenter study.
Annunziata Dattola, Nicoletta Bernardini, Francesca Svara, Anna Balato, Giacomo Caldarola, Francesco Loconsole

J Dermatolog Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.
Piergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, Laura Atzori, Anna Balato, Francesco Loconsole

Dermatol Ther (Heidelb)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.
Elena Campione, Fabio Artosi, Ruslana Gaeta Shumak, Alessandro Giunta, Giuseppe Argenziano, Francesco Loconsole

Pharmaceuticals (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Francesco Loconsole

Dermatol Ther (Heidelb)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OPT-In; Optimized Patient Treatment Outcomes in Plaque Psoriasis: A 3-Year State-Transition Treatment-Sequencing Model in the Italian Setting.
Sarah Alulis, Nicoletta Bernardini, Martina Burlando, Antonio Costanzo, Pier Cesare Francesa Morel, Francesco Loconsole

Dermatol Ther (Heidelb)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab for severe psoriasis: a case of successful retreatment without induction after 15 months of discontinuation.
Edoardo Mortato, Silvia Baratta, Riccardo Viola, Anna P DE Caro, Francesco Loconsole

Ital J Dermatol Venerol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis